Royalty Report: Drugs, Therapeutic, Disease – Collection: 245952

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Diagnostic
  • Drug Discovery
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245952

License Grant
Included with the collaboration agreement is a license agreement.

The Licensor and the Japanese Licensee wish to develop and market novel therapeutic products based on compounds identified pursuant to the Collaboration Agreement.  The amendment clarifies, Licensor will screen compounds to identify specific compounds having promising activity for lowering serum LDL-cholesterol through the regulation of CYP7 gene expression or through interaction with the nuclear hormone receptor LXRa.

In the License agreement,  Licensor grants the Japanese Licensee the right and license, with the right to sublicense, to develop Preclinical Candidates and to make, have made, use and sell Products under the Licensor Technology and the Licensor-owned and jointly owned Program Technology. The license granted herein shall be exclusive, even as to Licensor, throughout the Licensees Territory.

License Property
Low Density Lipoprotein Receptor ('LDL-R') shall mean that sequence of amino acids commonly characterized as Low Density Lipoprotein Receptor in the scientific literature published as of the Effective Date.

Product shall mean any pharmaceutical product, including all formulations, line extensions or modes of administration thereof, for use within the Field, which contains an active ingredient which is or is derived from a Preclinical Candidate to this Agreement.

Field of Use
The Field shall mean therapeutic treatment of human disease, primarily by means of activation of LDL-R gene expression to effectively lower serum LDL-cholesterol.

IPSCIO Record ID: 240609

License Grant
Licensor hereby grants the Japanese Licensee the right and license, with the right to sublicense, to develop, make, have made, use and sell Products in the Territory solely within the Field under Licensor Technology and the Licensor-owned and jointly owned Collaboration Technology. The license granted herein shall be exclusive, even as to Licensor, except for the co-promotion rights retained by Licensor as set forth in this agreement. All Licensed Compounds and the patents and patent applications included in the Licensor Technology and the Licensor-owned and jointly owned Collaboration Technology licensed under this subsection is updated from time to time to include new Licensed Compounds and the patent applications and issued patents relating thereto. Licensee covenants and agrees that it will not use, directly or indirectly, the Licensor Technology or Licensor solely owned Collaboration Technology for any purpose other than developing, making, having made, using or selling Products in the Territory in the Field under this Agreement.
License Property
Product shall mean any pharmaceutical product, including all formulations, line extensions or modes of administration thereof, which contains a Licensed Compound as an active ingredient or compound which is derived from a Licensed Compound for replacement of the Licensed Compound.

Licensed Compound shall mean a compound which is an Active Compound and which is recommended by the Research Committee and selected by Licensee for GLP Toxicology Studies and further development under the License Agreement.

Active Compound shall mean each Licensee or Licensor Substance which meets the criteria set forth (including any such Substance which was screened in Assays prior to the Effective Date and for which the Research Committee determines that such criteria are met), and each derivative or analogue thereof developed in the course of, but not after, the Research Program or the Tail End Period, if such derivative or analog thereof meets the criteria set forth.

The collaboration agreement is to discover and develop antibacterial drugs based on the two principal targets in the Licensor's anti-bacterial program.

Field of Use
This agreement pertains to the drug industry relating to novel therapeutic products.  Field shall mean therapeutic treatment of bacterial infections in humans with anti-bacterial pharmaceutical products which have activity against the Targets.

IPSCIO Record ID: 211864

License Grant
For the Non-Exclusive Research License to Licensor Base Technology, Licensor grants a non-exclusive, world-wide license under the Base Technology to conduct research and development activities pursuant to the Research Plan, with no right to sublicense.   Licensor also grants the right to sublicense or transfer the rights granted under the Collaboration Technology to: Affiliates; and to Third Parties.
License Property
License agreement is for the development of orally bioavailable small-molecule compounds identified through the application of PTC’s proprietary GEMS (Gene Expression Modulation by Small Molecules) technology.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.

The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Field of Use
Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

This agreement pertains to drug discovery.

IPSCIO Record ID: 249719

License Grant
Licensor grants the Japanese Licensee an exclusive, worldwide, right and license, within the Territory, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property and Joint Program Patent Rights, as embodied in or related to any Designated Compounds, to research, develop, make, have made and use such Designated Compound to develop Licensed Products and to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.

This agreement includes non-exclusive terms as well.

License Property
The licensed property includes:
(a) the Ne0Morph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Candidate Compound A,
(e) the Candidate Compound B,
(d) the Candidate Compound C, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof and
(e) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Program, which is Controlled by Licensor, primarily relates to a Designated Compound or Licensed Products, whether or not patentable.

NeoMorph Chemistry means the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focused Libraries means those compounds synthesized by Licensor derived from Active Compounds identified by Licensee in bioassays or functional assays NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising at least 10,000,000 different compounds.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets. Licensor has certain technology and know-how, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Field of Use
The Licensees intended use is for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

The Field means treatment of any disease in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.